NEW YORK--(BUSINESS WIRE)--Pfizer Oncology announced today that it will present new data from the company’s pipeline, including two novel, dual PI3K/mTOR (phosphatidylinositol 3-kinase / mammalian target of rapamycin) inhibitors (PF-046915021 and PKI-587, also known as PF-05212384);2 crizotinib (PF-02341066), an ALK (anaplastic lymphoma kinase) inhibitor that also inhibits c-MET (c-mesenchymal-epithelial transition factor);3 and PF-04605412, an anti-a5ß1 inhibitor.4 Data from these, and other investigational compounds, including sunitinib,5 axitinib,6 and figitumumab,7 will be presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C., from April 17 through April 21.
